MARJAN
The Organising Committee for the Ras Al Khaimah New Year’s Eve celebration is planning yet another Guinness World Records-worthy spectacular pyrotechnic fireworks performance, which will feature pyrodrones, lights, colours and shapes to welcome 2022.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20211101005544/en/
Covering a 4.7km stretch along the waterfront between Al-Marjan Island and Al-Hamra Village, the 12-minute spectacle, open to the public and set to clinch two Guinness World Records, will be accompanied by a crescendo of modern and dynamic music to reflect a new spirit of optimism.
#RAKNYE2022 will also welcome the public to enjoy a host of family oriented activities and events that will keep visitors enthralled until the countdown starts for the mesmersising display. These activities will spread across Al -Marjan Island and along the waterfront between Al- Marjan Island and Al -Hamra Village, which includes entertainment, children’s play areas, family gathering areas, and F&B outlets, details of which will be announced soon. To keep up-to-date, please log on to raknye.com .
The high-level Organising Committee reiterated its focus on taking all precautionary measures to ensure the safety of the public through co-ordination with the National Authority for Emergency, Crisis & Disaster Management and the Ministry of Health & Prevention. Safety protocols are to be followed by all attendees. The Committee, which consists of members from Marjan, Ras Al Khaimah Police, Ras Al Khaimah Government Media Office, Ras Al Khaimah Tourism Development Authority, Ras Al Khaimah Chamber of Commerce, Public Works, Ras Al Khaimah Municipality, Al Hamra and others, is leading the preparations for the event.
Earlier this year, Ras Al Khaimah welcomed 2021 with a dazzling 10-minute fireworks show that underlined the UAE’s message of hope, peace and achievements. Ras Al Khaimah made history with the New Year’s Eve Gala of 2020, which won the GUINNESS WORLD RECORDS™ titles for the ‘Most Unmanned Aerial Vehicles for Launching Fireworks Simultaneously’ and the ‘Longest Fireworks Waterfall.’ The Emirate also secured two GUINNESS WORLD RECORDS™ for the ‘Longest chain of fireworks’ and the ‘Longest straight line of fireworks’ with the 2019 New Year’s Eve Fireworks.
To access the video, please visit: #RAKNYE2022
*Source: AETOSWire
View source version on businesswire.com: https://www.businesswire.com/news/home/20211101005544/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
World FZO Concludes Its 11th World Congress in Hainan13.10.2025 12:14:00 CEST | Press release
More than 1,200 Participants from 70 Countries and 16 High-Level Ministerial Delegations The World Free Zones Organization concluded its 11th Annual World Congress in Hainan, hosted from October 10-12. The event attracted more than 1,200 participants from 70 countries, along with 16 high-level ministerial delegations and representatives of international economic and trade organisations. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251013845341/en/ HE Miguel Lecaro, Ambassador of the Republic of Panama to China, receiving the flag from H.E. Dr. Mohammed Al Zarooni (Photo: AETOSWire) The final day featured the Annual General Assembly meeting, during which a set of strategic resolutions aimed at enhancing the organisation’s operational framework and strengthening its global network of free zones was adopted. Elections were also held for the World FZO Board of Directors for a new term. The closing ceremony was attended by Liu
BeOne Medicines’ Sonrotoclax Granted Breakthrough Therapy Designation by U.S. FDA13.10.2025 12:00:00 CEST | Press release
Breakthrough designation based on early, positive results of a Phase 1/2 study of sonrotoclax in patients with relapsed or refractory mantle cell lymphoma (MCL)BeOne to participate in Project Orbis program, supporting efforts to rapidly advance global access BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation (BTD) for sonrotoclax, a next-generation and potentially best-in-class investigational BCL2 inhibitor, for the treatment of adult patients with relapsed or refractory (R/R) mantle cell lymphoma (MCL). Additionally, the FDA has accepted BeOne’s request for participation in Project Orbis, an initiative that provides a framework for concurrent submission and review of oncology products among participating global health authorities. “Breakthrough Therapy Designation is reserved for medicines with the potential to transform outcomes for pati
Datassential Names Pascal Hartwig General Manager of EMEA, Releases First-Annual Top Chains in Europe Report13.10.2025 09:00:00 CEST | Press release
Datassential, the leading global food and beverage intelligence platform, announced the appointment of Pascal Hartwig as General Manager of EMEA. This expansion is part of Datassential's ongoing strategy to shape the future of food and beverage intelligence with a unified platform that delivers scale, speed, and precision for every customer type across the foodservice industry, including operators, manufacturers, distributors and suppliers. Hartwig’s leadership marks a pivotal step in positioning Datassential as the definitive source of truth in Europe, the Middle East, and Africa — building on its North American dominance to establish a stronger global footprint. Pascal was previously the Chief Product Officer at BeZero Carbon, and held senior leadership roles at S&P Global Market Intelligence. During his career, Pascal has established a strong track record in financial services, data solutions, product innovation and delivering value to customers. “Pascal's appointment reflects Datas
I-Pulse Welcomes Codelco as Strategic Investor13.10.2025 07:00:00 CEST | Press release
World’s Largest Copper Producer Joins Mining Majors Backing I-Pulse TechnologyI-Pulse Employs High Pulsed Power to Create Disruptive Solutions for Resource Discovery, Mining, Manufacturing, Agriculture and Geothermal Energy I-Pulse Co-Founder, Chairman and CEO Robert Friedland and Laurent Frescaline, Co-Founder and Chief Technology Officer, are pleased to welcome Codelco as the company’s latest strategic investor and key partner in the development and commercialization of its disruptive pulsed power technologies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251012216264/en/ I-Pulse Co-Founder Chairman and CEO Robert Friedland and Codelco Chairman Máximo Pacheco Codelco, the world’s largest copper miner, will provide capital and real-world experience to accelerate the commercialization of I-Pulse’s breakthrough innovations for drilling, continuous underground mining, tunnelling and rock crushing. Codelco joins world leading
AdvanCell to Present Promising Clinical Trial Results of ADVC001, a Novel Lead-212-based PSMA-targeted Alpha Therapy for Prostate Cancer, at ESMO 202513.10.2025 01:31:00 CEST | Press release
Results from the Phase 1b dose escalation of the TheraPb Phase 1/2 trial are the first clinical data for a Lead-212 (212Pb)-based-PSMA radioligand therapy The abstract presents a favorable safety profile for 212Pb-ADVC001 and promising anti-tumor activity, underscoring its potential to enhance therapeutic options for patients with metastatic prostate cancer The upcoming presentation at ESMO will feature updated safety and efficacy results from all seven Phase 1b treatment cohorts AdvanCell, a clinical-stage radiopharmaceutical company developing innovative targeted alpha therapies for cancer, announces a presentation at the European Society for Medical Oncology (ESMO) Congress, taking place in Berlin, Germany, from October 17-21, 2025. The presentation will feature promising results from the Phase 1b dose escalation of the Phase 1/2 TheraPb study, evaluating ADVC001, a Lead-212-based PSMA-targeted alpha therapy, in metastatic castration-resistant prostate cancer (mCRPC). This will be t
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom